Haier Biomedicine, founded in 2005, was listed on the Shanghai Stock Exchange Science and Technology Innovation Board in 2019 (stock code: 688139). It is a service provider of life sciences and medical innovation digital scenario solutions based on the transformation of the Internet of Things. With the goal of creating the best user experience, the company provides smart laboratories, digital hospitals, and smart public services for life science users such as pharmaceutical companies, universities, and research institutions, as well as medical and health users such as hospitals, disease control, blood stations, and grassroots public health. Comprehensive solution for digital scenarios represented by hygiene, smart blood use, etc.

The company has always adhered to technological leadership, promoted scientific and technological innovation, and led industrial transformation. Since breaking through the low-temperature technology of biomedical medicine and breaking foreign monopoly, the company has continued to invest in new technologies and has now formed eight major technical platforms such as automation, separation, consumables, and reagents, and has successively broken through high-precision identification, positioning and grabbing technology and high-precision frequency conversion control technology. , visual recognition technology, laboratory consumables manufacturing technology and other core technologies, lay out microbial culture, environmental simulation, centrifugation, polymer materials and other fields, and accelerate the strengthening, expansion and extension of its own business layout. At the same time, the company actively integrates into national strategies such as technological power, digital China, and healthy China, and takes the lead in integrating emerging technologies such as the Internet of Things, artificial intelligence, and cloud computing, and pioneering the launch of comprehensive digital scenario solutions represented by smart blood use and smart vaccination. , and continue to expand to smart laboratories, hospital drug automation, public health physical examinations and other scenarios, leading the digital and intelligent transformation of the biomedical industry.

The company has always adhered to the vision of "making life better", and its products and solutions have been applied to more than 140 countries and regions around the world. In the domestic market, it covers tens of thousands of hospitals, biotechnology companies, university research institutions, disease control, plasma stations, testing institutions and other end users, including the General Hospital of the People's Liberation Army of China (301 Hospital), Shanghai Ruijin Hospital, WuXi AppTec, Shanghai Fudan University, China Center for Disease Control and Prevention, Hualan Biology, Hengrui Medicine, Fosun Pharma and many other well-known institutions; in the international market, the network layout is constantly improved, the local layout is strengthened, and it is in line with the World Health Organization (WHO) and the United Nations Children's Fund. More than 40 international organizations including UNICEF have maintained long-term and continuous cooperative relations.